Oramed Pharmaceuticals (ORMP)
(Delayed Data from NSDQ)
$2.10 USD
-0.08 (-3.67%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $2.10 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Oramed Pharmaceuticals Inc. [ORMP]
Reports for Purchase
Showing records 41 - 60 ( 80 total )
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Additional Milestone Payment Received; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Capital-Efficient Operating Trends Continue; Phase 2b Trial Progress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
First Patient Enrolled in Oral Insulin NASH Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
OWL833 Transaction Provides Benchmark for ORMD-0901; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Oral Protein Administration Patent Allowed; Clinical Trial Underway; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Integrium Services Agreement Inked; Upcoming Conference Presentation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
ORMP-0801 NASH Clinical Study Permission Granted; Patent Estate Expanded; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Pivotal Development Pathway Promulgated for Oral Insulin; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
ORMD-0801 Phase 3 Initiation Approaching; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
ORMD-0801 Phase 3 Initiation Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Oramed Pharmaceuticals Inc.
Industry: Medical - Products
Looking Towards Next Round of Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.